Company profile
Elite Pharmaceuticals, Inc.
OTC: ELTP · Healthcare · Drug Manufacturers - Specialty & Generic
#311 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
77B+FH 91DQ 57GM 79SS 71
v0.1 · 65/100 weight · provisional
↑ return on assets, operating margin · ↓ filing timeliness, workforce scale
Methodology →Revenue TTM
$148.9M
Rev growth YoY (TTM)
+77.1%
Net income (FY)
$44.9M
Employees
65
as of 2026-08-12
Market cap
$387.8M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$148.9M$148.9M2026
Net income$44.9M$44.9M2026
Operating income$49.1M$49.1M2026
Total assets$138.3M$138.3M2026
Liabilities$39.4M$39.4M2026
Equity$98.9M$98.9M2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY20
FY22
FY22
FY23
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2026
By product
Manufacturing99%
Licensing1%
By geography
Not disclosed.
The read
What is Elite Pharmaceuticals, Inc.’s revenue?
Elite Pharmaceuticals, Inc. booked $148.9M in FY2026 revenue, growing 77% year over year — faster than most Healthcare companies we track, at a 30.1% net margin.
Peers · Healthcare
AirSculpt Technologies, Inc.58CMacroGenics, Inc.54DNeuronetics, Inc.59CGRAIL Inc.51DCronos Group Inc.69BKaryopharm Therapeutics Inc.49DNeighbors
Bergen →Key facts
CEONasrat Hakim
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNorthvale, NJ
ExchangeOTC: ELTP
Employees65
IPO date2000-02-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.